Supplementary Material

Supplementary Table 1: Clinical and demographic characteristics of hospitalized patients

		COVID (+)	COVID (-)	p-value ^a
Total Admissions		5,482	53,284	
Total Hospitalization Days		64,980	526,783	
Total HASPIs		49	244	
HASPI Rate		7.5 per 10,000 days	4.6 per 10,000 days	
Pressure Ulcer Risk at Admission ^b		19 (15-20)	19 (16-21)	<0.001
Female Sex		2,635 (47.6%)	26,620 (49.7%)	0.003
Age (Years)		69.4 (58.8-79.8)	66.3 (53.5-76.7)	<0.001
	White	3,513 (63.5%)	37,962 (70.9%)	
Race	Black	1,623 (29.3%)	12,654 (23.6%)	<0.001
	Other	395 (7.1%)	2,912 (5.4%)	
Hospitalization Length (Days)		8 (6-14)	7 (6-11)	<0.001
ICU Admission: Yes		2,210 (40.0%)	18,656 (34.9%)	<0.001
Intubation: Yes		104 (1.9%)	602 (1.1%)	<0.001

during the study period.

Bolded values denote statistically significant p-values.

^aBased on Wilcoxon-rank sum test for continuous variable comparisons and Chi-squared test for categorical variable comparisons.

^bBased on Braden risk assessment score closest to admission. Note that a lower score equates to greater risk for ulcer formation.

		HASPI (+)	HASPI (-)	p-value ^a	
N		49	5,482		
Pressure Ulcer Risk at Admission ^b		14 (12-16.5)	19 (15-20)	<0.001	
Female Sex		17 (34.7%)	2,618 (47.8%)	0.08	
Age (Years)		66.3 (56.7-74.9)	69.4 (58.9-79.8)	0.22	
	White	29 (59.2%)	3,484 (63.6%)		
Race	Black	19 (38.8%)	1,604 (29.3%)	0.20	
	Other	1 (2.0%)	394 (7.2%)		
Hospitalization Length (Days)		29 (19.5-35)	8 (6-14)	<0.001	
	Hypertension	31 (63.3%)	3,230 (58.9%)	0.53	
Co-morbidities	COPD	13 (26.5%)	976 (17.8%)	0.11	
	Diabetes	23 (46.9%)	1,912 (34.9%)	0.08	
	Hospitalization Only	4 (8.2%)	3,306 (60.3%)		
Hernital Course Severity	ICU	25 (51.0%)	1,456 (26.6%)	-0.001	
Hospital Course Severity	Ventilation		65 (1.2%)	<0.001	
	Death	11 (22.5%)	655 (22.5%)		

Supplementary Table 2: Comparison of hospital course in COVID-19 (+) patients with and without HASPIs.

Bolded values denote statistically significant p-values.

^aBased on Wilcoxon-rank sum test for continuous variable comparisons and Chi-squared or Fisher's Exact tests for categorical variables comparisons.

^bBased on Braden risk assessment score closest to admission.

Supplementary Table 3: Multivariable ordinal regression for worsening hospital course severity in COVID-19 (+) patients.

Outcome	Regression Estimate(95% CI)	p-value ^a	
HASPI ^b : Yes vs. No	2.2 (1.8-2.8)	<0.001	
Age (Per additional year)	0.99 (0.99-1.00)	0.42	
Hypertension: Yes vs. No	0.93 (0.88-0.99)	0.01	
COPD ^c : Yes vs. No	1.00 (0.99-1.1)	0.11	
Diabetes: Yes vs. No	1.1 (1.0-1.2)	<0.001	

Bolded values denote statistically significant p-values.

^aThese p-values represent multivariable ordinal regression analysis controlling for age and patient co-morbidities (hypertension, chronic obstructive pulmonary disease, congestive heart failure, and diabetes) with disease severity as the outcome.

^bHASPI: Hospital-acquired sacral pressure injury.

^cCOPD: Chronic obstructive pulmonary disease.

	COVID (+)	COVID (-)	p-value ^a
N	47	247	
30-day morbidity ^b	8 (16.3%)	28 (11.5%)	0.34
Debridement: Yes	7 (14.3%)	14 (5.7%)	0.047
HASPI Infection: Yes	4 (8.2%)	20 (8.2%)	0.99

Supplementary Table 4: Thirty-day HASPI-related morbidity.

Bolded values denote statistically significant p-values.

^aBased on Fisher's Exact tests.

^bMorbidity is defined as an aggregate of either requiring surgical debridement of HASPI or infection of HASPI from time of admission to 30-days after hospital discharge.

Supplementary Table 5: ICD-10 codes used to search for healthcare acquired sacral pressure

injury.

L89.150, L89.151, L89.152, L89.153, L89.154, L89.159 - pressure ulcer of sacral region (various stages)

L98.429- non-pressure ulcer of sacrum


L98.499- non-pressure chronic ulcer of skin

L89.30, L89.31, L89.32, L89.302- pressure ulcer of buttocks

L98.411, L98.499- non-pressure ulcer of buttocks

L89.322, L89.323, L89.324, L89.312, L89.313, L89.314, L89.156, L89.90- pressure ulcer of left buttock (stages 2,3,4, or unspecified), right buttock (stages 2,3,4, or unspecified)


Supplementary Figure 1



Supplementary Fig. 1. Diagram showing the recruitment process.

(A) Among the 143,527 patients hospitalized at our institution during our defined study period (March 2020-December 2020), 58,766 patients met our inclusion/exclusion criteria and comprised our study cohort. A total of 3,352 patients had a diagnosis of sacral ulcer during their hospitalization with or without an image of their sacral region in their electronic medical records. Of these patients, 2,992 had their sacral ulcers documented present on admission (POA) and 67 were seen at an outside hospital and were excluded from our study. Our final study cohort consisted of 293 patients with HASPIs in the COVID-19(+) and COVID-19(-) groups.

Supplementary Figure 2



Supplementary Fig. 2. Diagram indicating sample sizes and molecular analysis parameters.

(A) Biopsies from COVID-19(+) patients with thrombotic vasculopathy (N=8), COVID-19(+) patients with pressure ulcers (N=5), and COVID-19(-) controls (N=10) were formalin fixed and paraffin embedded for histological analysis and staining to look at immune cell type specific markers. In addition, FFPE samples were utilized for NanoString analysis of mRNA expression in order to assess up- and down-regulated pathways as well as cell type scoring.